Versions - Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial.

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Cover Image

    Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial. by Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y Neven, Leo Heyndrickx, Johan Michiels, Elisabeth Willems, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, Véronique Olislagers, Alexandra Waegemans, Mathieu Verbrugghe, Marie-Noëlle Schmickler, Steven Van Gucht, Katelijne Dierick, Arnaud Marchant, Isabelle Desombere, Kevin K Ariën, Maria E Goossens

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:
  2. 2
    Cover Image

    Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial by Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y. Neven, Leo Heyndrickx, Johan Michiels, Elisabeth Willems, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, Véronique Olislagers, Alexandra Waegemans, Mathieu Verbrugghe, Marie-Noëlle Schmickler, Steven Van Gucht, Katelijne Dierick, Arnaud Marchant, Isabelle Desombere, Kevin K. Ariën, Maria E. Goossens

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:

Search Tools: